Bevacizumab Biosimilar - Ultra Low Endotoxin

Human

VEGF

>1mg/ml

Human IgG1

Humanized

Aflibercept Biosimilar - Research Grade (ICH4015), Ranibizumab Biosimilar - Research Grade (ICH4031), Brolucizumab Biosimilar - Research Grade (ICH5197), Suvemcitug Biosimilar - Research Grade (ICH5889), Tarcocimab Biosimilar - Research Grade (ICH5901), Varisacumab Biosimilar - Research Grade (ICH5969)

https://www.imgt.org/mAb-DB/

ICH3001-100ml ICH3002-100ml ICH3003-100ml

P15692

7422

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of bevacizumab, provided strictly for research use only. It is a fully human IgG1 monoclonal antibody engineered to recognize and bind vascular endothelial growth factor A (VEGF-A), the same target as the originator drug, and functions by capturing soluble VEGF-A so it cannot engage its receptors. The research-grade format makes it a convenient tool for scientists studying angiogenesis, VEGF signaling, and antibody biology: it serves as a well-defined positive control in VEGF neutralization and binding assays, a reference reagent for developing or benchmarking ELISAs and SPR/BLI methods, an isotype-matched human IgG1 comparator, and a starting point for ADC or bispecific engineering workflows. It is supplied low endotoxin (research grade under 1 EU/mg, ultra-low under 0.5 EU/mg) and available in bulk milligram-to-gram quantities to support screening, assay development, and preclinical in-vitro and in-vivo model work. It is not the clinical drug and is not intended for human or veterinary use, diagnosis, or treatment. VEGF-A (gene VEGFA; UniProt P15692) is a secreted, disulfide-linked homodimeric glycoprotein and the prototypical member of the vascular endothelial growth factor family. Alternative splicing generates several isoforms (such as VEGF121, VEGF165, and VEGF189) that differ in heparin and neuropilin binding. VEGF-A is the master regulator of both developmental and pathological angiogenesis: it drives endothelial cell proliferation, migration, survival, and vascular permeability. It signals primarily through the receptor tyrosine kinases VEGFR-1 (FLT1) and VEGFR-2 (KDR), with VEGFR-2 mediating most pro-angiogenic responses, and is modulated by neuropilin co-receptors. Because tumors and other diseased tissues co-opt VEGF-A to build new blood supply, sequestering VEGF-A to block receptor engagement is a central strategy in oncology and ophthalmology, making it a heavily studied node in vascular biology.

Vascular endothelial growth factor

Detects human VEGF. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Bevacizumab.

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Phosphate buffered saline (PBS) pH 7.2,with no carrier protein, potassium or preservatives added. BSA and Azide free.

Stable for at least one week when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at –80°C. Avoid Repeated Freeze Thaw Cycles.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

SIM0007

Bevacizumab (anti-VEGF) Biosimilar - Ultra Low Endotoxin

Q: Is the Bevacizumab biosimilar available in gram quantities?

A: Yes - it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: Is this Bevacizumab biosimilar suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Bevacizumab biosimilar target?

A: It is an unconjugated, non-therapeutic biosimilar analog of Bevacizumab that binds human VEGF; for research use only (RUO).